Spirocyclic compounds as tryptophan hydroxylase inhibitors
US10946018B2 · kind B2 · utility
5Cited by
8References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 16, 2020 |
| Grant date | Mar 16, 2021 |
| Priority date | — |
| Expiry date | Apr 16, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.